000118252 001__ 118252 000118252 005__ 20230519145528.0 000118252 0247_ $$2doi$$a10.1016/j.schres.2021.08.021 000118252 0248_ $$2sideral$$a126839 000118252 037__ $$aART-2021-126839 000118252 041__ $$aeng 000118252 100__ $$aAmoretti S. 000118252 245__ $$aCognitive clusters in first-episode psychosis 000118252 260__ $$c2021 000118252 5060_ $$aAccess copy available to the general public$$fUnrestricted 000118252 5203_ $$aImpairments in a broad range of cognitive domains have been consistently reported in some individuals with first-episode psychosis (FEP). Cognitive deficits can be observed during the prodromal stage. However, the course of cognitive deficits is still unclear. The aim of this study was to identify cognitive subgroups over time and to compare their sociodemographic, clinical and functional profiles. A total of 114 patients with Schizophrenia Spectrum Disorders were included in the present study. We assessed subjects through psychiatric scales and eight neuropsychological tests at baseline and at two-year follow-up visit. We performed the Partition Around Medoids algorithm with all cognitive variables. Furthermore, we performed a logistic regression to identify the predictors related to the different cognitive clusters at follow-up. Two distinct subgroups were found: the first cluster characterized by cognitive impairment and a second cluster had relatively intact cognition in comparison with norms. Up to 54.7% of patients with cognitive deficits at baseline tended to improve during the first two years of treatment. Patients with intact cognition at follow-up had a higher socioeconomic status, later age of onset, lower negative symptoms and a higher cognitive reserve (CR) at baseline. CR and age of onset were the baseline variables that predicted cognitive impairment. This research allows us to obtain a better understanding of the heterogeneous profile of psychotic disorders. Identifying the characteristics of patients who will present a cognitive impairment could improve early detection and intervention. These results suggest that enhancing CR could contribute to improving the course of the illness. © 2021 Elsevier B.V. 000118252 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/ 000118252 590__ $$a4.662$$b2021 000118252 591__ $$aPSYCHIATRY$$b64 / 157 = 0.408$$c2021$$dQ2$$eT2 000118252 591__ $$aPSYCHIATRY$$b47 / 144 = 0.326$$c2021$$dQ2$$eT1 000118252 592__ $$a1.451$$b2021 000118252 593__ $$aPsychiatry and Mental Health$$c2021$$dQ1 000118252 593__ $$aBiological Psychiatry$$c2021$$dQ1 000118252 594__ $$a8.0$$b2021 000118252 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000118252 700__ $$aRabelo-da-Ponte F.D. 000118252 700__ $$aRosa A.R. 000118252 700__ $$aMezquida G. 000118252 700__ $$aSánchez-Torres A.M. 000118252 700__ $$aFraguas D. 000118252 700__ $$aCabrera B. 000118252 700__ $$0(orcid)0000-0002-9098-655X$$aLobo A.$$uUniversidad de Zaragoza 000118252 700__ $$aGonzález-Pinto A. 000118252 700__ $$aPina-Camacho L. 000118252 700__ $$aCorripio I. 000118252 700__ $$aVieta E. 000118252 700__ $$aTorrent C. 000118252 700__ $$ade la Serna E. 000118252 700__ $$aBergé D. 000118252 700__ $$aBioque M. 000118252 700__ $$aGarriga M. 000118252 700__ $$aSerra M. 000118252 700__ $$aCuesta M.J. 000118252 700__ $$aBernardo M. 000118252 700__ $$aPEPs Group 000118252 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría 000118252 773__ $$g237 (2021), 31-39$$pSchizophr. res.$$tSCHIZOPHRENIA RESEARCH$$x0920-9964 000118252 8564_ $$s892859$$uhttps://zaguan.unizar.es/record/118252/files/texto_completo.pdf$$yVersión publicada 000118252 8564_ $$s2398524$$uhttps://zaguan.unizar.es/record/118252/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000118252 909CO $$ooai:zaguan.unizar.es:118252$$particulos$$pdriver 000118252 951__ $$a2023-05-18-15:28:11 000118252 980__ $$aARTICLE